The herb medicine formula "chong Lou Fu Fang" increases the cytotoxicity of chemotherapeutic agents and down-regulates the expression of chemotherapeutic agent resistance-related genes in human gastric cancer cells in vitro

Evidence-based Complementary and Alternative Medicine

Volumn 2011, Issue , 2011, Pages

  Liu, Baorui ^a   Liu, Yongping ^a,b   Ling, Yang ^b   Hu, Wenjing ^a   Xie, Li ^a   Yu, Lixia ^a   Qian, Xiaoping ^a   Zhang, Binxia ^c  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

^c Department of Internal Medicine   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHONG LOU FU FANG; DOCETAXEL; FLUOROURACIL; HERBACEOUS AGENT; OXALIPLATIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG POTENTIATION; FRUCTUS FORSYTHIAE; GENE EXPRESSION; HERBAL MEDICINE; HUMAN; HUMAN CELL; IN VITRO STUDY; MEDICINAL PLANT; PRIORITY JOURNAL; RADIX CODONOPSIS; RHIZOMA PARIDIS; STOMACH CANCER;

EID: 80052746471     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1093/ecam/nep175     Document Type: Article

References (35)

1. Leung W. K., Wu M.-S., Kakugawa Y., Kim J. J., Yeoh K.-G., Goh K. L., Wu K.-C., Wu D.-C., Sollano J., Kachintorn U., Gotoda T., Lin J.-T., You W.-C., Ng E. K., Sung J. J., Screening for gastric cancer in Asia: current evidence and practice The Lancet Oncology 2008 9 3 279 287 (Pubitemid 351722947)
2. Kamangar F., Dores G. M., Anderson W. F., Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world Journal of Clinical Oncology 2006 24 14 2137 2150 (Pubitemid 46655601)
3. Hundahl S. A., Phillips J. L., Menck H. R., The National Cancer Data Base report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: fifth Edition American Joint Committee on Cancer staging, proximal disease, and the 'different disease' hypothesis Cancer 2000 88 4 921 932 (Pubitemid 30091113)
4. Ajani J. A., Evolving chemotherapy for advanced gastric cancer Oncologist 2005 10 3 49 58 (Pubitemid 43153809)
5. Richardson M. A., Sanders T., Palmer J. L., Greisinger A., Singletary S. E., Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology Journal of Clinical Oncology 2000 18 13 2505 2514 (Pubitemid 30432515)
6. Boon H., Stewart M., Kennard M. A., Gray R., Sawka C., Brown J. B., McWilliam C., Gavin A., Baron R. A., Aaron D., Haines-Kamka T., Use of complementary/alternative medicine by breast cancer survivors in Ontario: prevalence and perceptions Journal of Clinical Oncology 2000 18 13 2515 2521 (Pubitemid 30432516)
7. Sparber A., Wootton J. C., Surveys of complementary and alternative medicine: part II. Use of alternative and complementary cancer therapies Journal of Alternative and Complementary Medicine 2001 7 3 281 287 (Pubitemid 32574902)
8. Cui Y., Shu X.-O., Gao Y., Wen W., Ruan Z.-X., Jin F., Zheng W., Use of complementary and alternative medicine by Chinese women with breast cancer Breast Cancer Research and Treatment 2004 85 3 263 270 (Pubitemid 38987261)
9. Wang Y. X., Li H. F., Progress of the anti-tumor study of Rhizoma Paridis Chinese Traditional and Herbal Drugs 2005 36 628 630
10. Sun J., Liu B.-R., Hu W.-J., Yu L.-X., Qian X.-P., In vitro anticancer activity of aqueous extracts and ethanol extracts of fifteen traditional Chinese medicines on human digestive tumor cell lines Phytotherapy Research 2007 21 11 1102 1104 (Pubitemid 350190311)
11. Cheng Z.-X., Liu B.-R., Qian X.-P., Ding Y.-T., Hu W.-J., Sun J., Yu L.-X., Proteomic analysis of anti-tumor effects by Rhizoma Paridis total saponin treatment in HepG2 cells Journal of Ethnopharmacology 2008 120 2 129 137
12. Li C.-Y., Xu H.-X., Han Q.-B., Wu T.-S., Quality assessment of Radix Codonopsis by quantitative nuclear magnetic resonance Journal of Chromatography A 2009 1216 11 2124 2129
13. Chou T.-C., Talalay P., Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Advances in Enzyme Regulation 1984 22 27 55
14. Livak K. J., Schmittgen T. D., Analysis of relative gene expression data using real-time quantitative PCR and the 2-CT method Methods 2001 25 4 402 408 (Pubitemid 34164012)
15. Eisenberg D. M., Davis R. B., Ettner S. L., Appel S., Wilkey S., Van Rompay M., Kessler R. C., Trends in alternative medicine use in the United States, 19901997: results of a follow-up national survey Journal of the American Medical Association 1998 280 18 1569 1575 (Pubitemid 28520643)
16. Li J., Sun G.-Z., Lin H.-S., Pei Y.-X., Qi X., An C., Yu J., Hua B.-J., The herb medicine formula Yang Wei Kang Liu improves the survival of late stage gastric cancer patients and induces the apoptosis of human gastric cancer cell line through Fas/Fas ligand and Bax/Bcl-2 pathways International Immunopharmacology 2008 8 9 1196 1206
17. Garg A. K., Buchholz T. A., Aggarwal B. B., Chemosensitization and radiosensitization of tumors by plant polyphenols Antioxidants and Redox Signaling 2005 7 11-12 1630 1647 (Pubitemid 41767998)
18. Wagner A. D., Grothe W., Haerting J., Kleber G., Grothey A., Fleig W. E., Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data Journal of Clinical Oncology 2006 24 18 2903 2909 (Pubitemid 46630593)
19. Al-Batran S.-E., Hartmann J. T., Probst S., Schmalenberg H., Hollerbach S., Hofheinz R., Rethwisch V., Seipelt G., Homann N., Wilhelm G., Schuch G., Stoehlmacher J., Derigs H. G., Hegewisch-Becker S., Grossmann J., Pauligk C., Atmaca A., Bokemeyer C., Knuth A., Jger E., Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie Journal of Clinical Oncology 2008 26 9 1435 1442
20. Van Cutsem E., Moiseyenko V. M., Tjulandin S., Majlis A., Constenla M., Boni C., Rodrigues A., Fodor M., Chao Y., Voznyi E., Risse M.-L., Ajani J. A., Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V25 study group Journal of Clinical Oncology 2006 24 31 4991 4997 (Pubitemid 46631401)
21. Matuo R., Sousa F. G., Escargueil A. E., Grivicich I., Garcia-Santos D., Chies J. A. B., Saffi J., Larsen A. K., Pgas Henriquesa J. A., 5-fluorouracil and its active metabolite FdUMP cause DNA damage in human SW620 colon adenocarcinoma cell line Journal of Applied Toxicology 2009 29 4 308 316
22. Faivre S., Chan D., Salinas R., Woynarowska B., Woynarowski J. M., DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells Biochemical Pharmacology 2003 66 2 225 237 (Pubitemid 36776396)
23. Matsuhashi N., Saio M., Matsuo A., Sugiyama Y., Saji S., Apoptosis induced by 5-fluorouracil, cisplatin and paclitaxel are associated with p53 gene status in gastric cancer cell lines International Journal of Oncology 2005 26 6 1563 1567
24. Schimming R., Mason K. A., Hunter N., Weil M., Kishi K., Milas L., Lack of correlation between mitotic arrest or apoptosis and antitumor effect of docetaxel Cancer Chemotherapy and Pharmacology 1999 43 2 165 172 (Pubitemid 29045036)
25. Yeh K.-H., Shun C.-T., Chen C.-L., Lin J.-T., Lee W.-J., Lee P.-H., Chen Y.-C., Cheng A.-L., High expression of thymidylate synthase is associated with the drug resistance of gastric carcinoma to high dose 5-fluorouracil-based systemic chemotherapy Cancer 1998 82 9 1626 1631 (Pubitemid 28208909)
26. Kuramochil H., Tanaka K., Oh D., Lehman B. J., Dunst C. M., Yang D. Y., de Meester S. R., Hagen J. A., Danenberg K. D., de Meester T. R., Danenberg P. V., Thymidylate synthase polymorphisms and mRNA expression are independent chemotherapy predictive markers in esophageal adenocarcinoma patients International Journal of Oncology 2008 32 1 201 208 (Pubitemid 351176079)
27. Reed E., Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy Cancer Treatment Reviews 1998 24 5 331 344 (Pubitemid 28537769)
28. De Silva I. U., McHugh P. J., Clingen P. H., Hartley J. A., Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells Molecular and Cellular Biology 2000 20 21 7980 7990
29. Hoeijmakers J. H. J., Genome maintenance mechanisms for preventing cancer Nature 2001 411 6835 366 374 (Pubitemid 32467046)
30. Metzger R., Leichman C. G., Danenberg K. D., Danenberg P. V., Lenz H.-J., Hayashi K., Groshen S., Salonga D., Cohen H., Laine L., Crookes P., Silberman H., Baranda J., Konda B., Leichman L., ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy Journal of Clinical Oncology 1998 16 1 309 316 (Pubitemid 28041614)
31. Rosell R., Cecere F., Santarpia M., Reguart N., Taron M., Predicting the outcome of chemotherapy for lung cancer Current Opinion in Pharmacology 2006 6 4 323 331
32. Sarries C., Haura E. B., Roig B., Taron M., Abad A., Scagliotti G., Rosell R., Pharmacogenomic strategies for developing customized chemotherapy in non-small cell lung cancer Pharmacogenomics 2002 3 6 763 780 (Pubitemid 35331411)
33. Sve P., Dumontet C., Is class III -tubulin a predictive factor in patients receiving tubulin-binding agents? The Lancet Oncology 2008 9 2 168 175 (Pubitemid 351150128)
34. Pusztai L., Markers predicting clinical benefit in breast cancer from microtubule-targeting agents Annals of Oncology 2007 18 xii15 xii20
35. Rouzier R., Rajan R., Wagner P., Hess K. R., Gold D. L., Stec J., Ayers M., Ross J. S., Zhang P., Buchholz T. A., Kuerer H., Green M., Arun B., Hortobagyi G. N., Symmans W. F., Pusztai L., Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer Proceedings of the National Academy of Sciences of the United States of America 2005 102 23 8315 8320 (Pubitemid 40800086)